{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:36:23Z","timestamp":1780875383389,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00417-018-4190-7","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T09:26:08Z","timestamp":1542965168000},"page":"273-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum"],"prefix":"10.1007","volume":"257","author":[{"given":"Maurizio","family":"Battaglia Parodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-7261","authenticated-orcid":false,"given":"Alessandro","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lloren\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cicinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"4190_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ajmg.a.34067","volume":"155A","author":"J Uitto","year":"2011","unstructured":"Uitto J, Bercovitch L, Terry SF, Terry PF (2011) Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment: summary of the 2010 PXE International Research Meeting. Am J Med Genet A 155A:1517\u20131526","journal-title":"Am J Med Genet A"},{"key":"4190_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archopht.123.7.923","volume":"123","author":"A Agarwal","year":"2005","unstructured":"Agarwal A, Patel P, Adkins T, Gass JD (2005) Spectrum of pattern dystrophy in pseudoxanthoma elasticum. Arch Ophthalmol 123:923\u2013928","journal-title":"Arch Ophthalmol"},{"key":"4190_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3928\/23258160-20150213-11","volume":"46","author":"MB Battaglia Parodi","year":"2015","unstructured":"Battaglia Parodi MB, Iacono P, Bandello F (2015) Pseudoxanthoma elasticum associated with vitelliform macular lesion. Ophthalmic Surg Lasers Imaging Retina 46:287\u2013288","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4190_CR4","doi-asserted-by":"publisher","unstructured":"Battaglia Parodi M, Casalino G, Iacono P, Introini U, Adamyan T, Bandello F (2017) The expanding clinical spectrum of choroidal excavation in macular dystrophies. Retina. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001805","DOI":"10.1097\/IAE.0000000000001805"},{"key":"4190_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0039-6257(82)90158-8","volume":"26","author":"JG Clarkson","year":"1982","unstructured":"Clarkson JG, Altman RD (1982) Angioid streaks. Surv Ophthalmol 26:235\u2013246","journal-title":"Surv Ophthalmol"},{"key":"4190_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0002-9394(14)71398-4","volume":"116","author":"JI Lim","year":"1993","unstructured":"Lim JI, Bressler NM, Marsh MJ, Bressler SB (1993) Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 116:414\u2013423","journal-title":"Am J Ophthalmol"},{"key":"4190_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00006982-199701000-00003","volume":"17","author":"A Pece","year":"1997","unstructured":"Pece A, Avanza P, Galli L, Brancato R (1997) Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina 17:12\u201316","journal-title":"Retina"},{"key":"4190_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/bjo.2008.143461","volume":"93","author":"TW Wiegand","year":"2009","unstructured":"Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS (2009) Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularization in patients with angioid streaks. Br J Ophthalmol 93:47\u201351","journal-title":"Br J Ophthalmol"},{"key":"4190_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000050899","volume":"215","author":"S Pozzo Da","year":"2001","unstructured":"Da Pozzo S, Battaglia Parodi M, Toto L, Ravalico G (2001) Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica 215:412\u2013414","journal-title":"Ophthalmologica"},{"key":"4190_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/IAE.0b013e3181f056ce","volume":"31","author":"SA Zweifel","year":"2011","unstructured":"Zweifel SA, Imamura Y, Freund KB, Spaide RF (2011) Multimodal fundus imaging of pseudoxanthoma elasticum. Retina 31:482\u2013491","journal-title":"Retina"},{"key":"4190_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fgene.2013.00014","volume":"4","author":"M Gliem","year":"2013","unstructured":"Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P (2013) An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 4:14","journal-title":"Front Genet"},{"key":"4190_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/IAE.0000000000000745","volume":"36","author":"J Tilleul","year":"2016","unstructured":"Tilleul J, Mimoun G, Querques G et al (2016) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: four-year follow-up. Retina 36:483\u2013491","journal-title":"Retina"},{"key":"4190_CR13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1097\/IAE.0000000000000605","volume":"35","author":"C Alag\u00f6z","year":"2015","unstructured":"Alag\u00f6z C, Alag\u00f6z N, \u00d6zkaya A et al (2015) Intravitreal bevacizumab in the treatment of choroidal neovascular membrane due to angioid streaks. Retina 35:2001\u20132010","journal-title":"Retina"},{"key":"4190_CR14","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1097\/IAE.0b013e3182914d2b","volume":"33","author":"M Gliem","year":"2013","unstructured":"Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P (2013) Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina 33:1300\u20131314","journal-title":"Retina"},{"key":"4190_CR15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/eye.2012.116","volume":"26","author":"M Shah","year":"2012","unstructured":"Shah M, Amoaku WM (2012) Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond) 26:1194\u20131198","journal-title":"Eye (Lond)"},{"key":"4190_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ajo.2011.03.022","volume":"152","author":"RP Finger","year":"2011","unstructured":"Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG (2011) Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol 152:695\u2013703","journal-title":"Am J Ophthalmol"},{"key":"4190_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1755-3768.2009.01836.x","volume":"89","author":"L Matri El","year":"2011","unstructured":"El Matri L, Kort F, Bouraoui R, Karim B, Chebil A, Chaker N (2011) Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. Acta Ophthalmol 89:641\u2013646","journal-title":"Acta Ophthalmol"},{"key":"4190_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3928\/15428877-20100726-04","volume":"41","author":"A Teixeira","year":"2010","unstructured":"Teixeira A, Mattos T, Velletri R et al (2010) Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 41:546\u2013549","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"4190_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ajo.2010.06.004","volume":"150","author":"G Mimoun","year":"2010","unstructured":"Mimoun G, Tilleul J, Leys A, Coscas G, Soubrane G, Souied EH (2010) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol 150:692\u2013700","journal-title":"Am J Ophthalmol"},{"key":"4190_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ajo.2016.03.017","volume":"165","author":"P Iacono","year":"2016","unstructured":"Iacono P, Battaglia Parodi M, La Spina C, Bandello F (2016) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks: 3-year follow-up study. Am J Ophthalmol 165:174\u2013178","journal-title":"Am J Ophthalmol"},{"key":"4190_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ajo.2013.10.015","volume":"157","author":"M Battaglia Parodi","year":"2014","unstructured":"Battaglia Parodi M, Iacono P, La Spina C et al (2014) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Am J Ophthalmol 157:374\u2013377","journal-title":"Am J Ophthalmol"},{"key":"4190_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1097\/IAE.0b013e31824b32e4","volume":"32","author":"V Vaclavik","year":"2012","unstructured":"Vaclavik V, Tran HV, Gaillard MC, Schorderet DF, Munier FL (2012) Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin\/RDS gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-VEGF (ranibizumab) intravitreal injections. Retina 32:1942\u20131949","journal-title":"Retina"},{"key":"4190_CR23","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1167\/iovs.10-5237","volume":"51","author":"M Battaglia Parodi","year":"2010","unstructured":"Battaglia Parodi M, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F (2010) Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 51:4358\u20134361","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4190_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/112067210001000315","volume":"10","author":"M Battaglia Parodi","year":"2000","unstructured":"Battaglia Parodi M, Di Crecchio L, Ravalico G (2000) Vascularized pigment epithelial detachment in adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol 10:266\u2013269","journal-title":"Eur J Ophthalmol"},{"key":"4190_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-4190-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T19:14:09Z","timestamp":1574450049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-4190-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4190"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-4190-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Battaglia Parodi M has the following financial disclosures: Bausch & Lomb Inc. (C). Bandello F has the following financial disclosures: Alcon (C), Allergan Plc.(C), Famila-Thea (C), Bayer Schering Pharma AG (C), Bausch & Lomb (C), Hoffmann-La-Roche (C), Novartis (C), Sanofi-Aventis (C), and Carl Zeiss AG (C). FR, AM, AA, and MVC have no financial disclosures. Lloren\u00e7 V has the following financial disclosures: Abbvie (G, C), Allergan(C), UCB(C). Adan A has the following financial disclosures: Abbvie (G, C), Allergan (G, C), UCB(C).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was approved by the local Institutional Review Board and adhered to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}